Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,365 | 189 | 1,159 |
| Samples | 544 | 102 | 437 |
| Peptides | 431 | 58 | 376 |
Function
LATS1 · Large tumor suppressor kinase 1
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. [provided by RefSeq, Apr 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 419 amino-acid changes on canonical ENST00000543571 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LATS1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LATS1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 7/42 17% | 25/612 4% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Germ Cell Tumour | 4/25 16% | 2/169 1% |
| Bladder Carcinoma | 3/58 5% | 26/956 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 18/810 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 27/1390 2% |
| Other Solid Cancers | 4/94 4% | 31/1515 2% |
| Melanoma | 6/210 3% | 40/1899 2% |
| Cervical Carcinoma | 2/35 6% | 7/422 2% |
| Colorectal Carcinoma | 10/143 7% | 52/3239 2% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Gastric Carcinoma | 1/74 1% | 31/1809 2% |
| Hepatocellular Carcinoma | 2/46 4% | 32/2210 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 8/752 1% |
| Ovarian Carcinoma | 2/109 2% | 12/998 1% |
| Biliary Tract Carcinoma | 2/54 4% | 9/950 1% |
| Neuroendocrine Tumour | 4/154 3% | 4/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 13/1574 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 21/2550 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 14/1592 1% |
| Meningioma | 1/3 33% | 1/252 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Other Sarcomas | 3/69 4% | 2/699 0% |
| Non-Cancerous | 2/104 2% | 4/830 0% |
| Breast Carcinoma | 6/144 4% | 15/3264 0% |
| Kidney Carcinoma | 1/85 1% | 11/1862 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
Mutation Distribution
Where LATS1 is mutated · all tissues, split by cell line vs tissue
How many mutations in LATS1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,365 mutations in LATS1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|